PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31092693-5	2019	This occurs partially as a result of cediranib inducing hypoxia, which suppresses expression of the HDR factors BRCA1/2 and RAD51 recombinase (RAD51).	cediranib	37-46	RAD51 recombinase	Homo sapiens	124-141	
31182430-2	2019	Cediranib may confer sensitivity to olaparib by increasing tumor hypoxia and inhibiting platelet-derived growth factor receptor, which reduces BRCA1/2 and RAD51 expression, thus decreasing homology-deficient DNA repair.	cediranib	0-9	RAD51 recombinase	Homo sapiens	155-160	
33742489-2	2021	BACKGROUND: Cediranib, a vascular endothelial growth factor receptor inhibitor, suppresses expression of BRCA1/2 and RAD51 inducing homologous recombination DNA repair deficiency (HRD) in several cancer cell lines and xenograft models [1].	cediranib	12-21	RAD51 recombinase	Homo sapiens	117-122	
31092693-5	2019	This occurs partially as a result of cediranib inducing hypoxia, which suppresses expression of the HDR factors BRCA1/2 and RAD51 recombinase (RAD51).	cediranib	37-46	RAD51 recombinase	Homo sapiens	124-129